13-Jan-2022 - High-Tech Gründerfonds Management GmbH

Pantherna Therapeutics secures EUR 4.0 Mio. follow-on financing to advance its therapeutic mRNA development programs  

Pantherna Therapeutics announces the successful completion of a follow-on financing round totaling EUR 4.0 Mio. led by existing investors Riesner Verwaltungs GmbH and High-Tech Gründerfonds. The proceeds of this round will be used to accelerate preclinical development activities for its lead program PAN004, an mRNA-based therapeutic for Acute Respiratory Distress Syndrome (ARDS).  

ARDS causes a life-threatening damage to the lungs induced by an excessive hyperinflammatory reaction of the lung tissue in response to bacterial and viral infections including SARS-CoV2 (COVID-19). No targeted therapy is available for this syndrome to prevent fluid retention and tissue damage to the lungs. Pantherna Therapeutics is developing a targeted therapy with a new mode of action by expressing a TIE-2 receptor agonist to restore endothelial barrier function.

"The new funds will be used to expand the PAN004 development activities and will also support Pantherna´s efforts to strengthen its R&D team and activities for advancing its mRNA therapeutics technology for new indications", Dr. Jörg Kaufmann, CSO at Pantherna Therapeutics.

"Qiagen developed the purification of RNA nearly 40 years ago, and in recent years the outstanding impact of mRNA-technology for vaccination became obvious. I am more than happy to follow now the development of mRNA-technology to the urgent need of targeted therapy", Prof. Detlev Riesner, Qiagen-co-founder and private investor of several Biotech companies.

"We are delighted to assist in the new funding round to bring Pantherna´s innovation a huge step closer to the clinic", Dr. Anke Caßing, Principal at High-Tech Gründerfonds.

Facts, background information, dossiers
  • financing
  • mRNA therapeutics
  • Acute Respiratory D…
More about High-Tech Gründerfonds Management
  • News

    Tubulis Closes €60 Million Series B Financing

    Tubulis announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), Bi ... more

    Biograil Secures Seed 2 Funding for Oral Delivery Device for Biologics

    Biograil ApS, a Copenhagen based biotech startup developing a unique oral device for delivery of biologics that would otherwise be injected, announced the closing of a Seed 2 funding of 3.2 million Euro. The Round was led by Danish Megatrend Invest a/s with strong support from other prior i ... more

    Kerry acquires c-LEcta

    High-Tech Gründerfonds (HTGF) sells its shares in c-LEcta after accompanying the company for 16 years. Kerry Group plc, a taste and nutrition company announces it has reached agreement to acquire c. 92% of the issued share capital of c-LEcta GmbH for a consideration of €137m (Consideration ... more

More about Pantherna Therapeutics
  • News

    Life science start-up Pantherna Therapeutics receives 7-digit investment

    Pantherna Therapeutics secures €3.5 million in a successful seed-financing round.The funds will be used to advance R&D activities and hire additional scientific staff. The Investors are the High-Tech Gründerfonds (HTGF), European Business Angel Prof. Detlev Riesner as well as the European I ... more

  • Companies

    Pantherna Therapeutics GmbH

    Pantherna Therapeutics is a privately-held biopharmaceutical Company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium. Pant ... more